Tag: Inflation reduction act

As of January 1, 2025, significant changes from the Inflation Reduction Act have impacted prescription drug costs for Trelegy users on Medicare. Understanding how much does Medicare pay for Trelegy now involves navigating these new rules, including a $2,000 annual out-of-pocket cap that can offer substantial savings for many beneficiaries.

Effective July 9, 2024, pharmaceutical company Indivior announced it would discontinue all sales and marketing activities for its schizophrenia drug, Perseris. This strategic move was not prompted by any safety or efficacy issues with the product but was a business decision based on financial viability, which answers the question: **Why is Perseris being discontinued**?. The market withdrawal was driven by increased payor management impacts and a competitive market landscape influenced by the Inflation Reduction Act.

In a July 2024 announcement, pharmaceutical company Indivior revealed it would cease promoting and selling its schizophrenia medication, Perseris. This decision, driven by market pressures and financial viability concerns rather than any safety or efficacy issues, left many asking: **why was Perseris discontinued**?